Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.17 - $6.17 $194,263 - $378,109
-61,282 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $20,546 - $67,763
-4,939 Reduced 7.46%
61,282 $330,000
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $717,173 - $1.22 Million
66,221 New
66,221 $895,000
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $2.55 Million - $4.92 Million
-175,961 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $2.79 Million - $4.07 Million
175,961 New
175,961 $3.8 Million
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $379,918 - $707,275
-12,485 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$46.46 - $68.49 $5.49 Million - $8.09 Million
-118,125 Reduced 90.44%
12,485 $761,000
Q2 2018

Aug 03, 2018

BUY
$46.25 - $104.45 $6.04 Million - $13.6 Million
130,610 New
130,610 $6.38 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $169M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.